Back to dashboard
CommercialCoverageMedium impact

08.02.06b, Tofersen (Qalsody®)

Independence Blue Cross·Pharmacy·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

Policy 08.02.06b addresses coverage and reimbursement for Tofersen (Qalsody®), a pharmacy treatment. This is a recent policy change effective January 1, 2025, that impacts how this medication is billed and reimbursed under commercial plans. The billing team must review the full policy details to determine specific prior authorization, coverage criteria, or reimbursement adjustments.

Action Required

Action needed
By December 31, 2024: Billing team must obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=01&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-02-06b to identify specific HCPCS codes for Tofersen, prior authorization requirements, and reimbursement rates. Before January 1, 2025: Update billing system with any new coverage rules, prior auth workflows, or documentation requirements identified in the policy. Notify providers and pharmacy staff of any changes to Tofersen billing procedures. Failure to implement required changes may result in claim denials or payment delays.

Related policy hubs